がん免疫療法の世界市場：2025～2030年の予測

がん免疫療法市場は、2025年の1,678億6,200万米ドルから2030年には3,412億7,300万米ドルまで、CAGR 15.25％で成長すると予測されています。

がん免疫療法市場は、がん罹患率の増加と、がん細胞と闘うために身体の免疫システムを利用する治療法の進歩によって、力強い成長を遂げています。免疫療法は、自然な防御機構を活用してがんを識別・除去し、従来の方法と比較して毒性を低減した標的治療の選択肢を提供します。市場は、研究開発への多額の投資、先進療法の採用拡大、がんに対する意識の高まりによって支えられています。しかし、高い治療費と長い規制当局の承認プロセスが市場拡大の課題となっています。このような課題にもかかわらず、同市場は、特にヘルスケアのインフラが整っている地域や、がん罹患率が上昇している新興国において、継続的な成長が見込まれています。

主な成長要因

先進免疫療法への投資

がん免疫療法市場は、大手製薬企業や研究機関による多額の投資によって支えられています。これらの投資は、チェックポイント阻害剤やCAR-T細胞療法など、有効性を高め副作用を最小限に抑える標的免疫療法の開発に重点を置いています。業界リーダー間の協力体制が新薬の開発を加速し、がん治療におけるアンメットニーズに対応し、患者の転帰を改善することで市場の成長を促進しています。

肺がん罹患率の上昇

喫煙や環境暴露などの要因による肺がん罹患率の増加は、市場成長に大きく寄与しています。肺がんは世界的に罹患率が高いため、免疫療法市場で大きなシェアを占めています。新興経済諸国における高額なヘルスケア支出や効果的な治療法の研究開発に支えられた免疫療法の採用は、特に肺がん特異的な治療法の需要をさらに促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場スナップショット

• 市場概要
• 市場の定義
• 調査範囲
• 市場セグメンテーション

第3章 ビジネス情勢

• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析
• 業界バリューチェーン分析
• ポリシーと規制
• 戦略的提言

第4章 技術展望

第5章 がん免疫療法の世界市場：タイプ別

• イントロダクション
• モノクローナル抗体（MAB）
• チェックポイント阻害剤
• サイトカイン
• がんワクチン
• 養子細胞移植

第6章 がん免疫療法の世界市場：用途別

• イントロダクション
• 黒色腫
• 肺がん
• 白血病
• 膀胱がん
• 乳がん
• 大腸がん
• その他

第7章 がん免疫療法の世界市場：エンドユーザー別

• イントロダクション
• 病院・診療所
• がん研究センター

第8章 がん免疫療法の世界市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • その他
• 中東・アフリカ
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 市場シェア分析
• 合併、買収、合意およびコラボレーション
• 競合ダッシュボード

第10章 企業プロファイル

• Servier
• Sanofi
• Xencor
• Pfizer Inc.
• Cellectis SA
• CytomX Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Nektar
• Eisai Co., Ltd.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.

第11章 付録

• 通貨
• 前提条件
• 基準年と予測年のタイムライン
• 利害関係者にとっての主なメリット
• 調査手法
• 略語

The global cancer immunotherapy market is expected to grow from USD 167.862 billion in 2025 to USD 341.273 billion in 2030, at a CAGR of 15.25%.

The global cancer immunotherapy market is experiencing robust growth, driven by the increasing prevalence of cancer and advancements in therapies that harness the body's immune system to combat cancer cells. Immunotherapy leverages natural defense mechanisms to identify and eliminate cancer, offering targeted treatment options with reduced toxicity compared to traditional methods. The market is propelled by significant investments in research and development, growing adoption of advanced therapies, and rising cancer awareness. However, high treatment costs and lengthy regulatory approval processes pose challenges to market expansion. Despite these hurdles, the market is poised for continued growth, particularly in regions with strong healthcare infrastructure and emerging economies with rising cancer incidences.

Key Growth Drivers

Investments in Advanced Immunotherapies

The cancer immunotherapy market is bolstered by substantial investments from major pharmaceutical companies and research organizations. These investments focus on developing targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, which enhance efficacy and minimize side effects. Collaborative efforts among industry leaders are accelerating the development of novel drugs, driving market growth by addressing unmet needs in cancer treatment and improving patient outcomes.

Rising Incidence of Lung Cancer

The increasing prevalence of lung cancer, driven by factors such as smoking and environmental exposures, significantly contributes to market growth. Lung cancer holds a substantial share of the immunotherapy market due to its high global incidence. The adoption of immunotherapies, supported by high healthcare expenditure in developed economies and ongoing research into effective treatments, is expected to further propel demand, particularly for lung cancer-specific therapies.

Market Segmentation

By Application

The cancer immunotherapy market is segmented into skin cancer, lung cancer, leukemia, bladder cancer, and others. Lung cancer dominates due to its high prevalence and the growing adoption of immunotherapies in regions with strong healthcare systems. Bladder cancer and leukemia also hold significant shares, driven by increased research and development investments targeting these cancer types, which require specialized immunotherapeutic approaches to improve patient outcomes.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. North America is expected to maintain a significant market share, driven by early adoption of innovative therapies, a high prevalence of cancer, and substantial R&D investments. The presence of key market players and a robust regulatory framework, including FDA approvals for immunotherapy drugs, further supports growth. Asia-Pacific is projected to experience rapid growth, fueled by an increasing cancer patient pool, rising awareness, and technological advancements in countries like India and China, where clinical trials for therapies like CAR-T are expanding.

Competitive Landscape

Key players, including Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier, are driving innovation through collaborative research and development of advanced immunotherapies. These companies focus on novel drug combinations and targeted therapies to enhance treatment efficacy and expand market reach.

The cancer immunotherapy market is set for significant growth, propelled by rising cancer incidences, particularly lung cancer, and substantial investments in advanced therapies. North America leads due to its strong healthcare infrastructure, while Asia-Pacific's rapid expansion reflects growing patient needs and clinical advancements. Despite challenges like high costs and regulatory delays, the market's trajectory remains positive, driven by ongoing innovation and the critical role of immunotherapy in transforming cancer treatment.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

The global cancer immunotherapy market has been analyzed through the following segments:

By Type

• Monoclonal antibodies (MABs)
• Checkpoint Inhibitors
• Cytokines
• Cancer vaccines
• Adoptive Cell Transfer

By Application

• Melanoma
• Lung Cancer
• Leukemias
• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Others

By End User

• Hospitals and Clinics
• Cancer Research Centers
• Canada

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• Italy
• United Kingdom
• Others
• Middle East and Africa
• Israel
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Monoclonal antibodies (MABs)
• 5.3. Checkpoint Inhibitors
• 5.4. Cytokines
• 5.5. Cancer vaccines
• 5.6. Adoptive Cell Transfer

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Melanoma
• 6.3. Lung Cancer
• 6.4. Leukemias
• 6.5. Bladder Cancer
• 6.6. Breast Cancer
• 6.7. Colorectal Cancer
• 6.8. Others

7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER

• 7.1. Introduction
• 7.2. Hospitals and Clinics
• 7.3. Cancer Research Centers

8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. Italy
  • 8.4.4. United Kingdom
  • 8.4.5. Others
• 8.5. Middle East & Africa
  • 8.5.1. Israel
  • 8.5.2. Saudi Arabia
  • 8.5.3. UAE
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. South Korea
  • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Servier
• 10.2. Sanofi
• 10.3. Xencor
• 10.4. Pfizer Inc.
• 10.5. Cellectis SA
• 10.6. CytomX Therapeutics, Inc.
• 10.7. Bristol-Myers Squibb Company
• 10.8. Nektar
• 10.9. Eisai Co., Ltd.
• 10.10. Merck & Co., Inc.
• 10.11. F. Hoffmann-La Roche Ltd.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations